MedPage Today

Current Landscape of Factor VIII and IX Inhibitor Testing in Hemophilia

Hemophilia A and B are X-linked bleeding disorders characterized by partial or complete absence of clotting factors VIII and IX (FVIII and FIX, respectively). FVIII and FIX are critical coagulation ...
Nasdaq

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or B ...
Monthly Prescribing Reference

Marstacimab Significantly Reduces Bleeding Rates in Hemophilia A, B With Inhibitors

Marstacimab significantly reduced ABR by 93% vs on-demand treatment over 12 months. Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with ...
MarketWatch

HYMPAVZI(R) (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

The MarketWatch News Department was not involved in the creation of this content. -- Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and ...
Monthly Prescribing Reference

Hympavzi Approved for Treatment of Hemophilia A or B

Results showed marstacimab was superior to on-demand factor replacement and was noninferior to prophylactic factor-based therapy. The Food and Drug Administration (FDA) has approved Hympavzi ...
Healio

FDA approves Hympavzi for hemophilia A or B without inhibitors

Please provide your email address to receive an email when new articles are posted on . The FDA approved marstacimab-hncq for treatment of certain individuals with hemophilia. The indication applies ...
MedPage Today

Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...
FierceBiotech

FDA Approves Baxter's RIXUBIS as First Recombinant Factor IX Treatment for Routine Prophylaxis of Hemophilia B

Approval brings patients first new rFIX treatment option in more than 15 years DEERFIELD, Ill.--June 27, 2013--Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug ...
Business Insider

Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events

Annualized bleeding rate (ABR) for all 15 participants was reduced by 98 percent, while annualized infusion rate (AIR) was reduced by 99 percent as of the May 7, 2018 data cutoff Range of steady-state ...
Nature

RFLPs of factor IX gene in Japanese haemophilia B families and gene deletion in two high-responder-inhibitor patients

Antonarakis, S.E., Waber, P.G., Kittur, S.D., Patel, B.S., Kazazian, H.H., Jr., Mellis, M.A., Counts, R.B., Stamatoyannopoulos, G., Bowie, E.J.W., Fass, D.N., Pittman ...
Nature

Immunological Investigation of a Christmas Factor Inhibitor by Means of Boyden's Technique

THE question whether the circulating anticoagulants are antibodies is still unsettled. An attempt was made to examine the Christmas factor inhibitor (factor IX inhibitor, or P.T.C. [plasma ...